论文部分内容阅读
目的:探讨洛丁新联合安博维在治疗高血压型肾炎中的降压及降蛋白效果。方法:回顾性分析我院2010年3月～2011年3月收治的36例高血压型肾炎患者的临床资料。将其均分为治疗组和对照组,治疗组应用洛丁新联合安博维进行治疗,对照组应用心痛定加中药进行治疗,比较两组的降压及降蛋白效果。结果:洛丁新联合安博维在治疗高血压型肾炎中的降压和降蛋白效果明显,两组具有显著性差异(P>0.05)。结论:洛丁新联合安博维对高血压型肾炎有明显的降压及降尿蛋白作用,且无明显副作用,对肝肾无明显损害,效果安全,是当前治疗肾炎较理想的药物,值得临床应用。
OBJECTIVE: To investigate the antihypertensive effect and the protein-lowering effect of the combination of loobin and angbine in the treatment of hypertensive nephritis. Methods: The clinical data of 36 patients with hypertensive nephritis treated in our hospital from March 2010 to March 2011 were retrospectively analyzed. The two groups were equally divided into treatment group and control group. The treatment group was treated with luodingxin combined with ambowei, while the control group was treated with xintongding plus traditional Chinese medicine. The antihypertensive and protein-lowering effects were compared between the two groups. Results: The effects of antihypertensive and antihypertensive drugs in the treatment of hypertensive nephritis were significantly different between the two groups (P> 0.05). CONCLUSION: The combination of LOBIN and AMV has obvious antihypertensive effect and antihypertensive effect on hypertensive nephritis with no obvious side effects and no obvious damage to the liver and kidney, and is safe and effective. It is an ideal drug for treating nephritis and is worth clinical treatment application.